Pretargeted antibody-guided radioimmunotherapy in a child affected by resistant anaplastic large cell lymphoma
Anaplastic large cell lymphoma (ALCL) is characterized by preferential paracortical and intrasinusoidal lymph node involvement by large anaplastic tumor cells expressing the CD30 antigen. Up to 80% of pediatric patients with ALCL can be cured with multi-agent chemotherapeutic regimens. Patients resistant to chemotherapy or suffering from early relapse have a poor prognosis and a poor chance of survival. In these cases, the highly aggressive clinical course of ALCL, associated with systemic symptoms and extranodal involvement, has been treated with different approaches in various cooperative trials, including conventional chemotherapy and human stem cell transplantation (HSCT). However, the optimal treatment has not yet been defined, in particular in cases of relapse.
More recently, radioimmunotherapy has been studied with encouraging results in cancer patients, including non-Hodgkin’s lymphoma.
Here we describe the case of a pediatric ALCL, relapsing after HSCT, treated with pretargeted antibody-guided radioimmunotherapy, obtaining a complete remission, with excellent quality of life over the past 10 months.
Document Type: Research Article
Affiliations: 1: Department of Public Health and Cell Biology, Pediatrics, University of Rome “Tor Vergata” c/o Ospedale “S. Eugenio”, Rome 2: Nuclear Medicine Division, European Institute of Oncology, Milan 3: Sigma-Tau Industrie Farmaceutiche Riunite SpA, Pomezia, Rome, Italy
Publication date: September 1, 2007